The move was announced by pharmaceuticals giant GlaxoSmithKline, which is jointly developing the vaccine, and Britain-based medical charity Wellcome Trust, which is contributing to a grant for the trials.
"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," a statement said.
"Human trials of this candidate vaccine, being co-developed by the US National Institutes of Health (NIH) and GlaxoSmithKline, are to be accelerated with funding from an international consortium in response to the Ebola epidemic."
A total of 1,552 people have died from the Ebola outbreak which erupted earlier this year in west Africa.
AFP